Question 1

Which developability parameters do you assess?

Accepted Answer

We assess key developability attributes such as stability (thermal/conformational), aggregation and self-association risk, solubility/formulation compatibility, charge-related heterogeneity (pI/variants), and sequence-based liabilities (e.g., deamidation/oxidation hotspots). Optional in silico immunogenicity risk screening can also be included.

Question 2

Is the assessment based on in silico predictions, experimental assays, or a combination of both?

Accepted Answer

We use a combination of both. AI-powered in silico predictions help us identify and prioritize the most relevant risks upfront, so we can design and optimize the experimental assays accordingly—focusing on the right parameters, faster, with less material.

Question 3

Can the assessment be performed on multiple antibody variants in parallel?

Accepted Answer

Yes — we can assess multiple antibody variants in parallel, enabling fast side-by-side comparison and selection of the most developable candidates.

Question 4

What analytical and biophysical methods are included?

Accepted Answer

Depending on your needs, the package can include Bradford or UV280 (concentration), SDS-PAGE (purity/integrity), ELISA (antigen binding), SEC-HPLC (purity/solubility/aggregation), DLS (size & aggregation), nanoDSF (thermostability), and SPR or BLI (affinity).

Question 5

What is the typical turnaround time?

Accepted Answer

Typical turnaround time is 2–3 weeks, depending on the number of variants and the selected assays.

Question 6

Can the service be adapted depending on molecule format (IgG, VHH, bispecifics)?

Accepted Answer

Yes — the assessment can be adapted to all antibody formats (e.g., IgG, VHH, bispecifics) and across species, with a methodology tailored to the specific molecule type.

Question 7

Do you provide clear go/no-go recommendations?

Accepted Answer

Yes — we deliver a detailed data report and provide clear go/no-go recommendations based on the results.

Question 8

Can the results guide subsequent optimization steps such as humanization or affinity maturation?

Accepted Answer

Yes — the results can be used to guide downstream optimization, including humanization service and affinity maturation services, by highlighting the key developability risks and priorities to address.

Question 9

Are your laboratories compliant with relevant quality standards (ISO, GMP-like)?

Accepted Answer

Yes — our laboratories operate under ISO-aligned quality standards, with GMP-like best practices applied where relevant to ensure robust traceability, documentation, and data integrity.

Question 10

Can you support downstream optimization if developability issues are identified?

Accepted Answer

Yes — if developability risks are identified, we can support downstream optimization, using AI-guided predictions to design and prioritize the most effective sequence and engineering strategies.

Question 11

Do you offer integrated packages combining discovery, engineering, and developability assessment?

Accepted Answer

Yes — we offer integrated end-to-end packages combining discovery, engineering, and developability assessment. Our teams work in synergy to support your program seamlessly from early candidate generation through final selection and optimization.

Antibody production

Accelerating Antibody Development During Global Crises

Antibodies in Targeted Drug Delivery: Enhancing Precision & Efficiency

Exploring Single B-Cell Technologies for Antibody Discovery

The Role of Antibodies in Diagnostics

Fine-Tuning Antibody Affinity: The Science Behind Antibody Affinity Maturation

Addressing Cross-Reactivity in Antibody Research

The Evolution of Antibody Production

Antibody Developability Improvement

Custom anti-GPCR antibodies

“The COVID-19 pandemic is helping us bridge the divide between virologists and immunologists” – Interview with Dr. Louisa James (QMUL)

Follow Us

Everything you need to know about the generation of antibody-drug conjugates (ADCs)

CAR-T cell engineering: strategies to overcome remaining limitations

Fundamental and advanced methods to improve monoclonal antibody production in vitro

The untapped potential of bispecific antibody therapies

What are the leading monoclonal antibody treatments for cancer?

“The COVID-19 pandemic is helping us bridge the divide between virologists and immunologists” – Interview with Dr. Louisa James (QMUL)

Reinventing IgY biotherapeutics – interview with Dr. Mara Freire (CICECO, University of Aveiro, Portugal)

How the environment shapes immune system development during pregnancy – interview with Dr. Melanie Conrad

“Cell-based phage display is helping us isolate more biologically relevant antibodies” – Interview with Dr. Mohamed Alfaleh (King Abdulaziz University)

“Researchers are not leveraging the speed and resolution of flow cytometry for clinical evaluation” – Interview with Prof. Tomáš Kalina (Charles University in Prague)

Antibody production

Accelerating Antibody Development During Global Crises

Follow Us

How are mouse monoclonal antibodies humanized: current approaches and limitations

Humanized vs. Fully Human Antibodies: What’s the Difference?

Advances in Animal-Free Monoclonal Antibody Production

Exploring Single B-Cell Technologies for Antibody Discovery

How to choose the best antibody generation technique for your project?

Everything you need to know about the generation of antibody-drug conjugates (ADCs)

CAR-T cell engineering: strategies to overcome remaining limitations

Fundamental and advanced methods to improve monoclonal antibody production in vitro

The untapped potential of bispecific antibody therapies

What are the leading monoclonal antibody treatments for cancer?

“The COVID-19 pandemic is helping us bridge the divide between virologists and immunologists” – Interview with Dr. Louisa James (QMUL)

Reinventing IgY biotherapeutics – interview with Dr. Mara Freire (CICECO, University of Aveiro, Portugal)

How the environment shapes immune system development during pregnancy – interview with Dr. Melanie Conrad

“Cell-based phage display is helping us isolate more biologically relevant antibodies” – Interview with Dr. Mohamed Alfaleh (King Abdulaziz University)

“Researchers are not leveraging the speed and resolution of flow cytometry for clinical evaluation” – Interview with Prof. Tomáš Kalina (Charles University in Prague)